| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857683 | SUN PHARM INDS INC | Stabilization of phenobarbital sodium for injection |
Apr, 2042
(17 years from now) | |
Sezaby is owned by Sun Pharm Inds Inc.
Sezaby contains Phenobarbital Sodium.
Sezaby has a total of 1 drug patent out of which 0 drug patents have expired.
Sezaby was authorised for market use on 17 November, 2022.
Sezaby is available in powder;intravenous dosage forms.
Sezaby can be used as method of treating neonatal seizures.
The generics of Sezaby are possible to be released after 07 April, 2042.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-414) | Nov 17, 2029 |
Drugs and Companies using PHENOBARBITAL SODIUM ingredient
Market Authorisation Date: 17 November, 2022
Treatment: Method of treating neonatal seizures
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
SEZABY family patents
